The tests high specificity (93%) and good sensitivity (78%), combined with its ease of use, make it a valuable tool for early detection of DPN, potentially leading to improved foot care and reduced risk of DFU
Research Use Only GHK-Cu has not been evaluated by the FDA for safety or efficacy in humans
Not commercially available through legitimate pharmaceutical channels
Nhng khi c b sung vo bn trong, glutathione cn mang hiu qu lm trng da, m nm tn nhang v chng lo ha
There are three impacts across the drug channel that immediately come to mind: Patient Savings (clear positive) High-deductible plan members will see real out-of-pocket relief Coinsurance payments drop proportionally with list price This addresses a major access barrier for GLP-1s Rebate-Focused Plans (coverage incentives) PBMs and health plans based on high rebates may need to renegotiate Some plans might reduce coverage if rebate guarantees shrink Responses by Eli Lilly/other GLP-1s will be important in the near term as plans prepare for 2027 strategies (which is right now) Medicaid Payments (budget pressure) State Medicaid agencies set their managed care rates based on upfront list (WAC) prices Lower list prices for these GLP-1s will be a budget relief for many states facing tight budgets right now Unlike the AMP cap removal in 2024 where manufacturers lowered list prices and the net price for the state went up (yes, drug pricing is complicated), the net price should be similar for the state, but with less upfront money required --- This move continues the saga of GLP-1 price wars, which is confusing for drug channels, but if nothing else, is a clear win for patients
